Alvotech to Participate in Two Upcoming Investor Conferences in September 2022

Rhea-AI Summary

Alvotech (NASDAQ: ALVO), a global biotech company, has announced participation in two investor conferences in September 2022. The leadership team will engage in fireside chats at:

• Citi’s 17th Annual Biopharma Conference on September 8 at 2:40 pm ET
• Morgan Stanley’s 20th Annual Global Healthcare Conference on September 12 at 2:15 pm ET

Webcast replays will be accessible on the Investors Section of Alvotech’s website for 90 days.

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in two upcoming investor conferences in September 2022. Representatives of Alvotech will hold two fireside chats:

• At Citi’s 17^th Annual Biopharma Conference: Thursday, September 8, 2:40 pm ET
• At Morgan Stanley’s 20th Annual Global Healthcare Conference: Monday, September 12,  2:15 pm ET

Following the conferences, a replay of the webcast will be available in the Investors Section of Alvotech’s website under News and Events – Events and Presentations, for 90 days.  

About Alvotech

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

CONTACTS

Alvotech Investor Relations
alvotech.ir[at]alvotech.com

Alvotech Corporate Communications
alvotech.media[at]alvotech.com

FAQ

What are the dates and times for Alvotech's investor conferences in September 2022?

Alvotech will participate in two investor conferences: the Citi’s 17th Annual Biopharma Conference on September 8 at 2:40 pm ET and the Morgan Stanley’s 20th Annual Global Healthcare Conference on September 12 at 2:15 pm ET.

Where can I find the replay of Alvotech's conference webcasts?

The replay of Alvotech's conference webcasts will be available in the Investors Section on Alvotech’s website for 90 days.

What is Alvotech's focus as a biotech company?

Alvotech focuses on the development and manufacture of biosimilar medicines for patients globally, aiming to be a leader in the biosimilar space.

How many biosimilar candidates does Alvotech currently have?

Alvotech has a pipeline containing eight biosimilar candidates targeting various conditions, including autoimmune disorders and cancer.

Who are some of Alvotech's commercial partners?

Alvotech's commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd., and several others across various global markets.